Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics

Table 1 Patient characteristics and potential prognostic factors

Characteristics	N	(%)	Median survival (months)	P ^b
Age				0.095
<40	7	4.3	83.0
40–49	31	19.3	33.1
50–59	62	38.5	36.0
60–69	33	20.5	46.0
≥70	26	16.1	60.3
Parity				0.019*
0–1	77	47.8	62.2
2–3	66	41.0	52.0
>3	15	9.3	45.0
Menopause				0.716
Yes	106	65.8	45.0
No	53	32.9	49.4
Ascites				0.735
Yes	62	38.5	37.0
No	97	60.2	59.5
Peritoneal metastasis				0.004^*
Yes	89	55.3	31.6
No	71	44.1	60.0
Lymphatic metastasis				0.905
Yes	69	42.9	26.3
No	91	56.5	58.6
FIGO stage				0.025^*
I	55	34.2	62.1
II	18	11.2	42.0
III	80	49.7	35.0
IV	7	4.3	18.3
Histotype				0.954
Serous	114	70.8	38.7
Mucinous	15	9.3	63.0
Endometrioid	13	8.1	59.0
Clear cell	9	5.6	60.4
Undifferentiated	10	6.2	29.0
Grade				0.415
G1	33	20.5	61.0
G2	57	35.4	55.0
G3	69	42.9	30.1
Tumor type^a				0.003^*
I	57	35.4	61.0
II	101	62.7	36.0
Residual disease				<0.0001^*
≤0.5 cm	119	73.9	58.0
>0.5 cm	40	24.8	19.4
Platinum resistance				<0.0001^*
Yes	36	22.4	22.0
No	123	76.4	58.0

^*statistical significance
^aBased on morphological and molecular genetic analysis, EOC are divided into two categories: type I tends to be low-grade neoplasms; while type II is high-grade neoplasms [35]
^bLog-rank test

ISSN: 1757-2215